The present invention is directed to a compound represented by Structural Formula (A):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I:

##STR00001##

as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I:

##STR00001##

as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.

Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.

A diarylethene compound represented by formula (I) ##STR00001##
wherein, Sg is a monovalent sugar residue formed by removing one hydroxyl group from a sugar compound or a monovalent protected sugar residue formed by removing one hydroxyl group from a sugar compound in which one or more other hydroxyl groups are protected, and wherein the sugar is selected from the group consisting of a six-membered ring sugar, a five-membered ring sugar, cyclitol, and oligosaccharides containing a six-membered ring sugar, a five-membered ring sugar, or cyclitol; U is —(CH.sub.2).sub.n—, —CH.sub.2—U′—, or —C(═O)— wherein n is an integer of 1 to 5, U′ is a C2-C10 branched alkylene group binding to Ar); and Ar is a group represented by formula (A1) or (A2); ##STR00002## wherein, X is S, SO.sub.2, NR.sub.3 in which R.sub.3 is a C1-C3 alkyl group, or O, R is C1-C4 alkyl group, R.sub.1 and R.sub.2 are independently a C1-C3 alkyl group, a is 0 or 1, b is an integer of 0-3, and * represents a bond with U; Y is a hydrogen atom or a halogen atom; and m is an integer of 3 to 5.

A diarylethene compound represented by formula (I) ##STR00001##
wherein, Sg is a monovalent sugar residue formed by removing one hydroxyl group from a sugar compound or a monovalent protected sugar residue formed by removing one hydroxyl group from a sugar compound in which one or more other hydroxyl groups are protected, and wherein the sugar is selected from the group consisting of a six-membered ring sugar, a five-membered ring sugar, cyclitol, and oligosaccharides containing a six-membered ring sugar, a five-membered ring sugar, or cyclitol; U is —(CH.sub.2).sub.n—, —CH.sub.2—U′—, or —C(═O)— wherein n is an integer of 1 to 5, U′ is a C2-C10 branched alkylene group binding to Ar); and Ar is a group represented by formula (A1) or (A2); ##STR00002## wherein, X is S, SO.sub.2, NR.sub.3 in which R.sub.3 is a C1-C3 alkyl group, or O, R is C1-C4 alkyl group, R.sub.1 and R.sub.2 are independently a C1-C3 alkyl group, a is 0 or 1, b is an integer of 0-3, and * represents a bond with U; Y is a hydrogen atom or a halogen atom; and m is an integer of 3 to 5.

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

The present disclosure relates to substituted thiophene carboxamides and analogues thereof of formula (I) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.

##STR00001##